Factors associated with utilization of neoadjuvant chemotherapy in charlson comorbidity zero non-metastatic muscle-invasive bladder cancer patients
Guideline-based best practice treatment for muscle invasive bladder cancer (MIBC) involves neoadjuvant chemotherapy followed by radical cystectomy (NACRC). Prior studies have shown that a minority of patients receive NACRC and older age and renal function are drivers of non-receipt of NACRC. This st...
Gespeichert in:
| Veröffentlicht in: | International Brazilian Journal of Urology Jg. 47; H. 4; S. 803 - 818 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Brazil
Sociedade Brasileira de Urologia
01.07.2021
|
| Schlagworte: | |
| ISSN: | 1677-5538, 1677-6119, 1677-6119 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Guideline-based best practice treatment for muscle invasive bladder cancer (MIBC) involves neoadjuvant chemotherapy followed by radical cystectomy (NACRC). Prior studies have shown that a minority of patients receive NACRC and older age and renal function are drivers of non-receipt of NACRC. This study investigates treatment rates and factors associated with not receiving NACRC in MIBC patients with lower comorbidity status most likely to be candidates for NACRC.
Retrospective United States National Cancer Database analysis from 2006 to 2015 of MIBC patients with Charlson comorbidity index (CCI) of zero. Analysis of NACRC treatment trends in higher CCI patients was also performed.
15.561 MIBC patients met inclusion criteria. 1.507 (9.7%) received NACRC within 9 months of diagnosis. NACRC increased over time (15.0% in 2015 compared to 3.6% in 2006). Higher NACRC was noted in females, cT3 or cT4 cancer, later year of diagnosis, and academic facility treatment. Lower utilization was noted for blacks and NACRC decreased with increasing age and CCI. Only 16.9% of patients aged 23-62 in the lowest age quartile with muscle invasive bladder cancer and CCI of 0 received NACRC.
Although utilization is increasing, receipt of NACRC remains low even in populations most likely to be candidates. Further study should continue to elucidate barriers to utilization of NACRC. |
|---|---|
| AbstractList | Guideline-based best practice treatment for muscle invasive bladder cancer (MIBC) involves neoadjuvant chemotherapy followed by radical cystectomy (NACRC). Prior studies have shown that a minority of patients receive NACRC and older age and renal function are drivers of non-receipt of NACRC. This study investigates treatment rates and factors associated with not receiving NACRC in MIBC patients with lower comorbidity status most likely to be candidates for NACRC.BACKGROUNDGuideline-based best practice treatment for muscle invasive bladder cancer (MIBC) involves neoadjuvant chemotherapy followed by radical cystectomy (NACRC). Prior studies have shown that a minority of patients receive NACRC and older age and renal function are drivers of non-receipt of NACRC. This study investigates treatment rates and factors associated with not receiving NACRC in MIBC patients with lower comorbidity status most likely to be candidates for NACRC.Retrospective United States National Cancer Database analysis from 2006 to 2015 of MIBC patients with Charlson comorbidity index (CCI) of zero. Analysis of NACRC treatment trends in higher CCI patients was also performed.MATERIALS AND METHODSRetrospective United States National Cancer Database analysis from 2006 to 2015 of MIBC patients with Charlson comorbidity index (CCI) of zero. Analysis of NACRC treatment trends in higher CCI patients was also performed.15.561 MIBC patients met inclusion criteria. 1.507 (9.7%) received NACRC within 9 months of diagnosis. NACRC increased over time (15.0% in 2015 compared to 3.6% in 2006). Higher NACRC was noted in females, cT3 or cT4 cancer, later year of diagnosis, and academic facility treatment. Lower utilization was noted for blacks and NACRC decreased with increasing age and CCI. Only 16.9% of patients aged 23-62 in the lowest age quartile with muscle invasive bladder cancer and CCI of 0 received NACRC.RESULTS15.561 MIBC patients met inclusion criteria. 1.507 (9.7%) received NACRC within 9 months of diagnosis. NACRC increased over time (15.0% in 2015 compared to 3.6% in 2006). Higher NACRC was noted in females, cT3 or cT4 cancer, later year of diagnosis, and academic facility treatment. Lower utilization was noted for blacks and NACRC decreased with increasing age and CCI. Only 16.9% of patients aged 23-62 in the lowest age quartile with muscle invasive bladder cancer and CCI of 0 received NACRC.Although utilization is increasing, receipt of NACRC remains low even in populations most likely to be candidates. Further study should continue to elucidate barriers to utilization of NACRC.CONCLUSIONSAlthough utilization is increasing, receipt of NACRC remains low even in populations most likely to be candidates. Further study should continue to elucidate barriers to utilization of NACRC. ABSTRACT Background: Guideline-based best practice treatment for muscle invasive bladder cancer (MIBC) involves neoadjuvant chemotherapy followed by radical cystectomy (NACRC). Prior studies have shown that a minority of patients receive NACRC and older age and renal function are drivers of non-receipt of NACRC. This study investigates treatment rates and factors associated with not receiving NACRC in MIBC patients with lower comorbidity status most likely to be candidates for NACRC. Materials and Methods: Retrospective United States National Cancer Database analysis from 2006 to 2015 of MIBC patients with Charlson comorbidity index (CCI) of zero. Analysis of NACRC treatment trends in higher CCI patients was also performed. Results: 15.561 MIBC patients met inclusion criteria. 1.507 (9.7%) received NACRC within 9 months of diagnosis. NACRC increased over time (15.0% in 2015 compared to 3.6% in 2006). Higher NACRC was noted in females, cT3 or cT4 cancer, later year of diagnosis, and academic facility treatment. Lower utilization was noted for blacks and NACRC decreased with increasing age and CCI. Only 16.9% of patients aged 23-62 in the lowest age quartile with muscle invasive bladder cancer and CCI of 0 received NACRC. Conclusions: Although utilization is increasing, receipt of NACRC remains low even in populations most likely to be candidates. Further study should continue to elucidate barriers to utilization of NACRC. Guideline-based best practice treatment for muscle invasive bladder cancer (MIBC) involves neoadjuvant chemotherapy followed by radical cystectomy (NACRC). Prior studies have shown that a minority of patients receive NACRC and older age and renal function are drivers of non-receipt of NACRC. This study investigates treatment rates and factors associated with not receiving NACRC in MIBC patients with lower comorbidity status most likely to be candidates for NACRC. Retrospective United States National Cancer Database analysis from 2006 to 2015 of MIBC patients with Charlson comorbidity index (CCI) of zero. Analysis of NACRC treatment trends in higher CCI patients was also performed. 15.561 MIBC patients met inclusion criteria. 1.507 (9.7%) received NACRC within 9 months of diagnosis. NACRC increased over time (15.0% in 2015 compared to 3.6% in 2006). Higher NACRC was noted in females, cT3 or cT4 cancer, later year of diagnosis, and academic facility treatment. Lower utilization was noted for blacks and NACRC decreased with increasing age and CCI. Only 16.9% of patients aged 23-62 in the lowest age quartile with muscle invasive bladder cancer and CCI of 0 received NACRC. Although utilization is increasing, receipt of NACRC remains low even in populations most likely to be candidates. Further study should continue to elucidate barriers to utilization of NACRC. |
| Author | Onge, Jarron M. Saint Lee, Eugene K. Ellis, Shellie D. Parker, William P. Au, Daniel Popoola, Taiye O. |
| Author_xml | – sequence: 1 givenname: Daniel orcidid: 0000-0002-0223-5407 surname: Au fullname: Au, Daniel organization: University of Kansas Health System, United States – sequence: 2 givenname: Eugene K. surname: Lee fullname: Lee, Eugene K. organization: University of Kansas Health System, United States – sequence: 3 givenname: Taiye O. surname: Popoola fullname: Popoola, Taiye O. organization: Health University of Kansas Health System, United States – sequence: 4 givenname: William P. surname: Parker fullname: Parker, William P. organization: University of Kansas Health System, United States – sequence: 5 givenname: Jarron M. Saint surname: Onge fullname: Onge, Jarron M. Saint organization: Health University of Kansas Health System, United States – sequence: 6 givenname: Shellie D. surname: Ellis fullname: Ellis, Shellie D. organization: Health University of Kansas Health System, United States |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33848073$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkk1v1DAQhiNURD_gLyBz45LFdr6cCwhVFCpV4gJnazKedL1K4sV2Fm3_Bn8YZ3epKCdOM_a8fmZsv5fZ2eQmyrI3gq9E1fJ3QdRNk1dVoVa228wrySVf8aotn2UXh1ItRHt2yhfZeXYZwoZz2fJGvMjOi0KVijfFRfbrBjA6HxiE4NBCJMN-2rhmc7SDfYBo3cRczyZyYDbzDqbIcE2ji2vysN0zO6U1-CEkHbrR-c4aG_fsgbxjae58pAghJhCycQ44UG6nHQS7I9YNYAx5hjBhCtskoimGl9nzHoZAr07xKvt-8-nb9Zf87uvn2-uPdzlWUsVcmJ4DKlWrRnJSqpRUlBxlr6DuhUKV0qriWBlFsjXQNzXUXWmMMDUnxOIquz1yjYON3no7gt9rB1YfNpy_1-DT3ANprBsSqi4FQl-SqZWhjktR9SglFkYm1vsjazt3IxlM9_AwPIE-rUx2re_dTqsiYbhIgLcngHc_ZgpRjzYgDQOkp5-DlpWQRVkKsUhf_93rscmfX02C9ihA70Lw1D9KBNeLg_TBQXqxhl4cpBcH6cVB6eyHf86ijQcbpLHt8B-E31lZ1bQ |
| CitedBy_id | crossref_primary_10_1016_j_clgc_2022_04_008 crossref_primary_10_1016_j_conctc_2022_100981 |
| Cites_doi | 10.1016/S0140-6736(12)60240-2 10.1016/j.eururo.2005.04.006 10.3233/BLC-150029 10.1245/s10434-016-5508-5 10.1111/bju.12601 10.1590/s1677-5538.ibju.2019.04.02 10.3322/caac.21332 10.1007/s00345-006-0113-z 10.1183/09031936.00059814 10.1038/ncpuro0322 10.1016/j.eururo.2015.08.037 10.1016/j.genm.2008.11.002 10.1053/j.ackd.2010.05.002 10.1016/j.canep.2016.04.012 10.1002/cncr.30029 10.1016/j.eururo.2007.10.069 10.1002/cncr.28520 10.1111/bju.12566 10.1016/j.eururo.2020.03.055 10.1016/j.juro.2007.01.055 10.1016/j.urology.2004.12.029 10.1590/s1677-5538.ibju.2020.99.01 10.1016/j.urology.2013.07.072 10.1245/s10434-019-07213-1 10.1016/j.euo.2018.03.001 |
| ContentType | Journal Article |
| Copyright | Copyright® by the International Brazilian Journal of Urology. |
| Copyright_xml | – notice: Copyright® by the International Brazilian Journal of Urology. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1590/s1677-5538.ibju.2020.0594 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1677-6119 |
| EndPage | 818 |
| ExternalDocumentID | oai_doaj_org_article_c67e18641caf4ed68deb0215fc22c3d2 PMC8321501 33848073 10_1590_s1677_5538_ibju_2020_0594 |
| Genre | Journal Article |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GrantInformation_xml | – fundername: NIGMS NIH HHS grantid: P20 GM130423 |
| GroupedDBID | --- 29J 2WC 53G 5GY 5VS AAYXX ABXHO ADBBV ADRAZ AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS APOWU AZFZN BAWUL BCNDV C1A CITATION CS3 DIK E3Z EBS EJD F5P FRP GROUPED_DOAJ HYE IPNFZ KQ8 M48 OK1 OVT PGMZT RIG RNS RPM RSC SCD TR2 W2D XSB CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c528t-1df0ac8868720e8842e340c2f8a6f18c8c2f550c5d8e29daf76a6b4dd1d60ecc3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 5 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000636273900013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1677-5538 1677-6119 |
| IngestDate | Fri Oct 03 12:42:44 EDT 2025 Thu Aug 21 17:50:42 EDT 2025 Fri Jul 11 13:08:39 EDT 2025 Thu Jan 02 22:37:33 EST 2025 Sat Nov 29 03:25:55 EST 2025 Tue Nov 18 22:24:48 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Neoadjuvant Therapy Cystectomy Urinary Bladder Neoplasms |
| Language | English |
| License | http://creativecommons.org/licenses/by/4.0 Copyright® by the International Brazilian Journal of Urology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c528t-1df0ac8868720e8842e340c2f8a6f18c8c2f550c5d8e29daf76a6b4dd1d60ecc3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 CONFLICT OF INTEREST None declared. |
| ORCID | 0000-0002-0223-5407 |
| OpenAccessLink | https://doaj.org/article/c67e18641caf4ed68deb0215fc22c3d2 |
| PMID | 33848073 |
| PQID | 2512344111 |
| PQPubID | 23479 |
| PageCount | 16 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_c67e18641caf4ed68deb0215fc22c3d2 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8321501 proquest_miscellaneous_2512344111 pubmed_primary_33848073 crossref_primary_10_1590_s1677_5538_ibju_2020_0594 crossref_citationtrail_10_1590_s1677_5538_ibju_2020_0594 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-07-01 |
| PublicationDateYYYYMMDD | 2021-07-01 |
| PublicationDate_xml | – month: 07 year: 2021 text: 2021-07-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Brazil |
| PublicationPlace_xml | – name: Brazil |
| PublicationTitle | International Brazilian Journal of Urology |
| PublicationTitleAlternate | Int Braz J Urol |
| PublicationYear | 2021 |
| Publisher | Sociedade Brasileira de Urologia |
| Publisher_xml | – name: Sociedade Brasileira de Urologia |
| References | Berry DL (ref27) 2015; 1 Konety BR (ref2) 2007; 177 Barocas DA (ref13) 2014; 120 Lin CC (ref29) 2016; 23 Dobruch J (ref22) 2016; 69 Mallin K (ref14) 2019; 26 Wong ML (ref30) 2018; 14 Schrag D (ref12) 2005; 65 Divo MJ (ref18) 2014; 44 Horstmann M (ref11) 2008; 5 Zaid HB (ref9) 2014; 83 Moschini M (ref28) 2019; 45 Barnett K (ref17) 2012; 380 Nielsen ME (ref26) 2014; 114 Gore JL (ref8) 2010; 102 Witjes JA (ref4) 2021; 79 Megwalu II (ref10) 2008; 53 Hamad J (ref20) 2020; 46 Hanna N (ref6) 2018; 1 Schinkel JK (ref23) 2016; 42 Black PC (ref24) 2006; 24 (ref15) 2017 Flaig TW (ref5) 2019; 17 Siegel RL (ref1) 2016; 66 (ref3) 2005; 48 Smith AB (ref7) 2014; 114 Weinstein JR (ref19) 2010; 17 Hollenbeck BK (ref25) 2005; 2 Rose TL (ref21) 2016; 122 Rabe-Hesketh S (ref16) 2012 33848074 - Int Braz J Urol. 2021 Jul-Aug;47(4):819-820. doi: 10.1590/S1677-5538.IBJU.2020.0594.1 |
| References_xml | – volume: 17 start-page: 591 year: 2019 ident: ref5 article-title: NCCN Guidelines Updates: Management of Muscle-Invasive Bladder Cancer publication-title: J Natl Compr Canc Netw – volume: 380 start-page: 37 year: 2012 ident: ref17 article-title: Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study publication-title: Lancet doi: 10.1016/S0140-6736(12)60240-2 – volume: 48 start-page: 202 year: 2005 ident: ref3 article-title: Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration publication-title: Eur Urol doi: 10.1016/j.eururo.2005.04.006 – start-page: 37 year: 2017 ident: ref15 – volume: 1 start-page: 151 year: 2015 ident: ref27 article-title: Treatment Decision Making in Patients with Bladder Cancer publication-title: Bladder Cancer doi: 10.3233/BLC-150029 – volume: 23 start-page: 4139 year: 2016 ident: ref29 article-title: Comparison of Comorbid Medical Conditions in the National Cancer Database and the SEER-Medicare Database publication-title: Ann Surg Oncol doi: 10.1245/s10434-016-5508-5 – volume: 114 start-page: 719 year: 2014 ident: ref7 article-title: Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base publication-title: BJU Int doi: 10.1111/bju.12601 – volume: 45 start-page: 655 year: 2019 ident: ref28 article-title: Enhanced recovery after surgery (ERAS) in radical cystectomy patients: from consensus to evidences publication-title: Int Braz J Urol doi: 10.1590/s1677-5538.ibju.2019.04.02 – volume: 66 start-page: 7 year: 2016 ident: ref1 article-title: Cancer statistics, 2016 publication-title: CA Cancer J Clin doi: 10.3322/caac.21332 – start-page: 871 volume-title: Multilevel and Longitudinal Modeling Using Stata year: 2012 ident: ref16 – volume: 24 start-page: 531 year: 2006 ident: ref24 article-title: Neoadjuvant chemotherapy for bladder cancer publication-title: World J Urol doi: 10.1007/s00345-006-0113-z – volume: 44 start-page: 1055 year: 2014 ident: ref18 article-title: Ageing and the epidemiology of multimorbidity publication-title: Eur Respir J doi: 10.1183/09031936.00059814 – volume: 2 start-page: 461 year: 2005 ident: ref25 article-title: Regionalization of care: centralizing complex surgical procedures publication-title: Nat Clin Pract Urol doi: 10.1038/ncpuro0322 – volume: 69 start-page: 300 year: 2016 ident: ref22 article-title: Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes publication-title: Eur Urol doi: 10.1016/j.eururo.2015.08.037 – volume: 5 start-page: 385 year: 2008 ident: ref11 article-title: Gender-specific differences in bladder cancer: a retrospective analysis publication-title: Gend Med doi: 10.1016/j.genm.2008.11.002 – volume: 17 start-page: 302 year: 2010 ident: ref19 article-title: The aging kidney: physiological changes publication-title: Adv Chronic Kidney Dis doi: 10.1053/j.ackd.2010.05.002 – volume: 42 start-page: 154 year: 2016 ident: ref23 article-title: Overall and recurrence-free survival among black and white bladder cancer patients in an equal-access health system publication-title: Cancer Epidemiol doi: 10.1016/j.canep.2016.04.012 – volume: 122 start-page: 2012 year: 2016 ident: ref21 article-title: Sex disparities in use of chemotherapy and survival in patients with advanced bladder cancer publication-title: Cancer doi: 10.1002/cncr.30029 – volume: 102 start-page: 802 year: 2010 ident: ref8 article-title: Uso de cistectomia radical para pacientes com câncer invasivo de bexiga publication-title: J Natl Cancer Inst – volume: 53 start-page: 581 year: 2008 ident: ref10 article-title: Prognostic impact of comorbidity in patients with bladder cancer publication-title: Eur Urol doi: 10.1016/j.eururo.2007.10.069 – volume: 120 start-page: 1018 year: 2014 ident: ref13 article-title: Racial variation in the quality of surgical care for bladder cancer publication-title: Cancer doi: 10.1002/cncr.28520 – volume: 114 start-page: 46 year: 2014 ident: ref26 article-title: Association of hospital volume with conditional 90-day mortality after cystectomy: an analysis of the National Cancer Data Base publication-title: BJU Int doi: 10.1111/bju.12566 – volume: 79 start-page: 82 year: 2021 ident: ref4 article-title: European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines publication-title: Eur Urol doi: 10.1016/j.eururo.2020.03.055 – volume: 177 start-page: 1636 year: 2007 ident: ref2 article-title: Bladder and upper tract urothelial cancer publication-title: J Urol doi: 10.1016/j.juro.2007.01.055 – volume: 65 start-page: 1118 year: 2005 ident: ref12 article-title: Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population publication-title: Urology doi: 10.1016/j.urology.2004.12.029 – volume: 46 start-page: 169 year: 2020 ident: ref20 article-title: Bladder preservation in muscle-invasive bladder cancer: a comprehensive review publication-title: Int Braz J Urol doi: 10.1590/s1677-5538.ibju.2020.99.01 – volume: 83 start-page: 75 year: 2014 ident: ref9 article-title: Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database publication-title: Urology doi: 10.1016/j.urology.2013.07.072 – volume: 26 start-page: 1604 year: 2019 ident: ref14 article-title: Incident Cases Captured in the National Cancer Database Compared with Those in U.S. Population Based Central Cancer Registries in 2012-2014 publication-title: Ann Surg Oncol doi: 10.1245/s10434-019-07213-1 – volume: 14 start-page: 10 year: 2018 ident: ref30 article-title: Comorbidity Assessment in the National Cancer Database for Patients With Surgically Resected Breast publication-title: Colorectal, or Lung Cancer – volume: 1 start-page: 83 year: 2018 ident: ref6 article-title: Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA publication-title: Eur Urol Oncol doi: 10.1016/j.euo.2018.03.001 – reference: 33848074 - Int Braz J Urol. 2021 Jul-Aug;47(4):819-820. doi: 10.1590/S1677-5538.IBJU.2020.0594.1 |
| SSID | ssj0029071 |
| Score | 2.2554622 |
| Snippet | Guideline-based best practice treatment for muscle invasive bladder cancer (MIBC) involves neoadjuvant chemotherapy followed by radical cystectomy (NACRC).... ABSTRACT Background: Guideline-based best practice treatment for muscle invasive bladder cancer (MIBC) involves neoadjuvant chemotherapy followed by radical... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 803 |
| SubjectTerms | Adult Aged Comorbidity Cystectomy Female Humans Middle Aged Muscles Neoadjuvant Therapy Neoplasm Invasiveness Original Retrospective Studies United States Urinary Bladder Neoplasm Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - surgery Young Adult |
| Title | Factors associated with utilization of neoadjuvant chemotherapy in charlson comorbidity zero non-metastatic muscle-invasive bladder cancer patients |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33848073 https://www.proquest.com/docview/2512344111 https://pubmed.ncbi.nlm.nih.gov/PMC8321501 https://doaj.org/article/c67e18641caf4ed68deb0215fc22c3d2 |
| Volume | 47 |
| WOSCitedRecordID | wos000636273900013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1677-6119 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0029071 issn: 1677-5538 databaseCode: DOA dateStart: 20030101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBZtKKWXktLXtmlQoFcnkmxL8rEJXXrpkkMLexOyHtRh1w5-BNq_kT-cGdtZsqXQHnoxxkZI1vfJmrFnviHkI3OWqcLyRAdeYgkzlVjlY8Ky6HPLo5d5ORabUKuVXq-LywelvjAmbJIHnibuzEkVuJYZdzZmwUvtQ4n7VHRCuNSPb1_obXKmnpKTsaRPwc46LqHfHNbzaVVeDeAJCnaK4iR7G9Co0_8n4_L3GMkHm87ykDyfrUX6aRrlC_Io1C_J7XKqkUPtPLXBU_ycSoFDmzmtkjaR1qGx_moAU7mnAM12zrX6SauaYrIV6jRSIFzTlpUHY5z-Cm1D66ZOtqG3mGlUObodOug5qeobi4HutNzgq6qlDtnS0lmWtXtFvi8_f7v4ksy1FRKXC90n3EdmndZSK8GC1pkIacaciNrKyLXTcArOi8u9DqLwNippZZl5z71kAHv6mhzAgMJbQnNwaL3OnSxCkclgyxTcIlXmLLPCWsEXRN9PuHGz8DjWv9gYdEAAKzNiZRArg1gZxMogVgsidk2vJ_WNf2l0jqjuGqCA9ngBaGVmWpm_0WpBTu45YWDB4V8UC7ANnUGDMAUjksODvZk4susK_H1M0U8XRO2xZ28s-3fq6sco6o0Vo3LG3_2Pwb8nzwSG3oxRxUfkoG-H8IE8cTd91bXH5LFa6-NxvcBxdfn1DobZIdU |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Factors+associated+with+utilization+of+neoadjuvant+chemotherapy+in+charlson+comorbidity+zero+non-metastatic+muscle-invasive+bladder+cancer+patients&rft.jtitle=International+Brazilian+journal+of+urology&rft.au=Au%2C+Daniel&rft.au=Lee%2C+Eugene+K.&rft.au=Popoola%2C+Taiye+O.&rft.au=Parker%2C+William+P.&rft.date=2021-07-01&rft.pub=Sociedade+Brasileira+de+Urologia&rft.issn=1677-5538&rft.eissn=1677-6119&rft.volume=47&rft.issue=4&rft.spage=803&rft.epage=818&rft_id=info:doi/10.1590%2FS1677-5538.IBJU.2020.0594&rft_id=info%3Apmid%2F33848073&rft.externalDocID=PMC8321501 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1677-5538&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1677-5538&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1677-5538&client=summon |